The prognostic value of histological classification and single histomorphological parameters in Hodgkin's Disease has been widely debated in the literature. Whereas several former studies identified single parameters to be of clinical relevance, some recent reports have doubted the prognostic value of histology under modern treatment.
Summary
The prognostic value of histological classification and single histomorphological parameters in Hodgkin's Disease has been widely debated in the literature. Whereas several former studies identified single parameters to be of clinical relevance, some recent reports have doubted the prognostic value of histology under modern treatment.
Grading of the largest histological category of Hodgkin's Disease, nodular sclerosis, has been controversially discussed concerning clinical relevance. Patients investigated in this study represent an outstanding collection since all of them were enrolled in the prospective multicenter clinical trial of the German Hodgkin Lymphoma Study Group. All of them had been staged uniformly according to the Ann Arbor system and had received stage-adapted modern treatment according to multimodality protocols. A subtle analysis of histology could represent a possible way to identify patients with a significantly better or worse prognosis. This new grading should help to avoid overtreatment in order to reduce severe therapy related side effects such as acute toxicity and chronic sequelae like cardio pulmonary complications and secondary neoplasias.
Introduction
Various approaches in histological classification of Hodgkin's disease (HD) have been developed since 1944 in order to predict prognosis on a histomorphological basis.
Because of the heterogeneity in clinical as well as histological appearance, prognostic factors have always been a subject of interest in HD. Although HD is nowadays generally considered to have a favorable outcome with modern therapeutic strategies, it remains important for pathologists and oncologists to establish reliable prognostic factors. In particular, distinguishing a low-risk group of patients might allow use of less aggressive treatment and thus reduce toxic side effects and late complications such as acute toxicity, chronic sequelaes like cardio pulmonary complications and secondary neoplasias.
Among the histological categories, nodular sclerosis was most commonly recognized in many early studies [1] [2] [3] [4] [5] [6] . This category was still very heterogeneous in its histological appearance as well as survival 7, 8 . In a large study of the British National Lymphoma Investigation (BNLI), division of the cases into NS grade 1 (low grade, NS1) and NS grade 2 (high grade, NS2) showed statistically significant differences in overall survival, complete response rates and disease-free survival 8 . The former study included the degree of cytological atypia as a criterion for distinguishing high and low grade NS in addition to the relative amounts of lymphocytes and Hodgkin/Reed-Sternberg (H/RS) cells.
The German Hodgkin Lymphoma Study Group (GHSG) also showed significant differences in clinical outcome between NS1 and NS2 treated according to modern, multimodality protocols 9, 10 and classified according to the British system. This significance was based on the differences in outcome in advanced stages of the disease only. No difference in clinical outcome could be observed between NS1 and NS2 in early and intermediate stages.
For personal use only. on . by guest www.bloodjournal.org From Grading of NS has been widely debated in the literature. While some reports supported the British grading system [9] [10] [11] [12] [13] [14] , significant survival differences could not be confirmed by several other groups [15] [16] [17] [18] . Furthermore, tissue eosinophilia, which has recently been shown to be an important independent prognostic factor in NS, is not included in the British grading system 19 .
A useful grading of the NS category is desirable, because it might be helpful in the development of risk-adapted therapies. Therefore, nine single histomorphological features and their clinical relevance were retrospectively evaluated in a large number of NS cases of the GHSG. The results were compared with the disputed BNLI grading system that was established with patients treated almost thirty years ago. The single components of the BNLI grading were thus re-evaluated in the context of optimal modern treatment. The aim was either to confirm the criteria or to propose a new grading of NS with risk factors adapted to new treatment and easier application for pathologists.
Patients and methods
All patients of this study (n=965) belong to the second study generation (HD4-6) of the GHSG which is a set of three parallel multicenter prospective clinical trials for early, intermediate and advanced stages, respectively. They were recruited from all over Germany between 1988 and 1993, staged uniformly according to the Ann Arbor criteria and had received stage-adapted modern treatment according to standardized protocols.
The patients of the study were aged 15 to 75 years at diagnosis 20, 21 . Detailed information about staging and treatment has been previously reported 19 . Follow up of up to nearly ten years (range 0 -111 month, median 70 months) with detailed clinical information was available for the evaluation of progression-free survival (PFS) and overall survival (OS). Firstly, clinical factors and CD15 positivity were selected by backward elimination (omitting morphological factors), considering both endpoints PFS and OS together.
Secondly, morphological factors were investigated by adding them one at a time to the previously selected factors and recording their significance with respect to both PFS and OS. A subset of those morphological factors which appeared to be prognostically relevant was chosen informally. Tentative prognostic scores were constructed using all plausible subsets of this initial subset. These tentative scores were then compared by estimating the hazard ratio (HR) for patients with at least one adverse factor compared with those having no adverse factors. The HR measures the degree of separation of prognostically poor from prognostically good cases.
Among the nine histomorphological parameters that were evaluated in the current study, syncytia and atypia were regarded as indicating a putative borderline between HD and non-Hodgkin lymphomas. Cases exhibiting these features were immunophenotyped by a large panel of antibodies to either ascertain the diagnosis of HD or exclude the case from the study (CD15, CD20, CD79a, CD30, CD3, CD43, LCA, EMA, Vimentin, ALK-1).
Results
Altogether 965 NS cases were evaluated in this study. 256 cases showed unusual histological features (i.e. syncytia or atypical morphology of the H/RS cells and variants).
In 135 of these cases, unstained slides or paraffin blocks were still available and they
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From were stained with a broad panel of ten immunohistochemical markers to either confirm the diagnosis of HD or exclude the case from the study (table 2) . Of all cases examined, only one case was excluded from the study because of an ALK-1 positivity that was weak and questionable, but still indicated a possible case of anaplastic large cell lymphoma. In the univariate analysis of the nine histomorphological criteria, the following parameters showed no significant association with PFS or OS: Sclerotic capsule thickening (17 figure 1 ). Tissue eosinophilia (43.0% of cases) showed a significant effect of PFS (p=0.002) and a highly significant association with OS (p<0.0001; figure 2).
In brief, there was no evidence that the parameters capsule, sclerosis, degree of involvement, syncytia and neutrophilia were associated with outcome. Necrosis was significantly associated with poor OS only. Atypia showed a negative trend for OS without statistical significance, but a significant effect on PFS. Lymphocyte depletion showed a significant effect on OS and a negative trend for PFS. Only the parameter eosinophilia showed highly significant results for PFS and OS (table 1) . Therefore, the four morphological factors eosinophilia, atypia, lymphocyte depletion and necrosis were selected as the initial subset of apparently multivariately relevant parameters. Table 3 displays the hazard ratios with respect to both PFS and OS for Cox models based on all those subsets of this initial subset which contain (at least) the strongly prognostic parameter eosinophilia. These results suggest that the best prognostic score, i.e. the score with the highest hazard ratio, should contain the following factors:
• Eosinophilia (approximately >5% of all cells or clusters in at least 5 high power fields
• Atypia (>25% bizarre and highly anaplastic appearing H/RS cells with pleomorphic nuclear features, hyperchromatism and highly irregular nuclear outlines)
• Lymphocyte depletion (<33% of all cells in the whole section) Alternatively, a 2-factor model would include only eosinophilia and atypia, but omit the factor lymphocyte depletion, the differences between both models being small. These two models share the greatest hazard ratios regarding both PFS and OS. They achieve markedly greater separation of prognostically poor and well doing patients than achieved with eosinophilia alone. We recommend the 3-factor score since the HR is slightly larger and the factor lymphocytopenia is easy to evaluate using our simplified approach Altogether 480 out of 964 NS cases showed at least one of the three risk factors (50%) and were recruited for the NS-HR category. Among the NS-HR cases, 78% showed only one risk factor, 19% showed two risk factors and 3% showed all three risk factors. No differences in clinical course were detectable between cases with only one versus cases with two or three risk factors (data not shown). Therefore, they were grouped together for further analysis. 85% of NS-HR cases showed tissue eosinophilia that has recently been shown to be the strongest histological prognostic factor in univariate and multivariate analysis 19 , but 15% of cases contributed to the NS-HR category without presence of ti ssue eosinophilia.
Thus, the large NS category was divided almost exactly into two halves, 50% belonging to the low-risk (NS-LR) and 50% belonging to the high-risk (NS-HR) group.
Among the 843 patients with complete clinical data, there were no significant differences in the age, sex and stage distributions between NS-LR and NS-HR or the two grading systems. Among the other risk factors tested, there were no significant differences between NS-LR and NS-HR. A correlation of the new grading with clinico-pathological factors showed a significant linear association with the IPS (p= 0.017) as the only factor.
There was a trend that NS-HR is associated with an increased ESR (p= 0.061) and large mediastinal tumor (p= 0.089), but both being not significant. Unlike the BNLI grading, there was no difference in the frequency of low hemoglobin in the new grading, compare 
Discussion
Nodular sclerosis is the category most commonly recognized in many early studies on Hodgkin's Disease in Western countries [1] [2] [3] [4] [5] [6] . Although NS is a well-defined category, it is still very heterogeneous in its histological appearance and survival 8 . The aim of the current study is to distinguish patients with a favorable prognosis who might be treated less aggressively thus developing less acute and late toxic complications such as second malignancies, chronic fatigue or fertility problems [30] [31] [32] [33] from patients with a poor prognosis who may benefit from aggressive treatment. All cases that did not fulfill the criteria mentioned above were classified as NS1. Patients with NS2 had a statistically significant worse clinical outcome, regardless of stage 8 . When grading according to this scheme, the cases of the GHSG also showed significant differences in clinical outcome between NS1 and NS2, but a subanalysis revealed that this significance was based on the differences in outcome in advanced stages of the disease only, i.e. 30% of the patients. No difference in clinical outcome was observed between NS1 and NS2 in early and intermediate stages 9 .
The BNLI grading is still not fully accepted and has been controversially debated in the literature. While some reports supported the British grading system 8;11-14 , significant prognostic differences could not be confirmed by several other groups [15] [16] [17] [18] . However, the findings in these studies applying the BNLI grading system require comment. In a study by Masih et al. 16 no significant results of the BNLI grading were found, but this study only included 42 patients, all at advanced stages. More than 10% had received radiation prior to investigation. The grading of this study showed a distribution of 31% NS1 and 69% NS2 cases. This selection of patients does therefore not seem comparable with a general distribution in developed countries and is furthermore too small to draw any substantial conclusions. The unusual distribution of NS1 and NS2 might be due to a differently interpreted use of the grading criteria or due to histological alterations after previous treatment.
Van Spronsen et al. 18 claimed that significant differences between NS1 and NS2 in the period 1972-1980 disappeared in the period 1981-1992 due to more intensive treatment.
This study included 109 patients in the latter period who received non-standardized treatment. Moreover, NS2 patients were treated more intensively. Thus, this study presents a distorted picture regarding the comparison of clinical outcome.
Two studies by Wijlhuizen et al. 13 and Ferry et al. 14 showed a significant effect of the BNLI grading on overall survival. This corresponds to the results of the GHSG. However, these studies lack a subanalysis of the impact of NS grading in the different stages of disease, probably due to the limited numbers of patients.
In summary, a detailed analysis of published studies on NS grading reveals no convincing data contradicting the prognostic value of grading NS for advanced stages. On the other hand, the former studies did not reveal any prognostic impact of the BNLI grading in early . This might have been due to the relatively difficult and equivocal applicability.
As we have previously reported, tissue eosinophilia is the strongest prognostic indicator in NS 19 . Eosinophilia was not included in the BNLI criteria. We therefore propose a new grading system that includes this important risk factor and should be easier to use than the BNLI criteria. The three criteria of the new grading system are:
• eosinophilia (approximately >5% of all cells or clusters in at least five High Power The new grading is a strong prognostic indicator not only for a small subset, but for the large majority of NS patients. These data imply that histology still plays an important role even under modern multi-modality treatment.
How should these data be used for future clinical trials ? Simplifying the grading of NS offers the chance for pathologists to grade every NS case reliably and we encourage other groups to confirm our grading score. Only based on a general acceptance of pathologists and the confirmatory results of other studies a critical review of all relevant risk factors in HD seems to make sence. Such revision should include both the long established clinical factors and more recent findings of biological and histopathological risk factors. The purpose of this grading approach is obvious: helping to prevent patients being overtreated and thus being unnecessarily at risk of severe therapy-related side effects such as acute toxicity and chronic sequelaes like cardio pulmonary complications and secondary neoplasias or fertility problems [30] [31] [32] [33] . 
